OmniNano Pharmaceuticals is a pharmaceutical technology startup located in Missouri City, TX. Omninano is developing nano-codelivery formulations with two drugs of distinct mechanisms of action for treating solid tumors. The foundational work has been done at the University of Texas MD Anderson Cancer Center and the University of Houston. Our lead product, ONP-001 is designed to treat pancreatic cancer. In 2022, 62,210 new pancreatic cases will be diagnosed in the US, with 49,830 deaths and a 5-year survival rate of only 11.5%. Extant drug therapies have very limited efficacy, with more than half of all pancreatic cancer patients dying within 12 months of diagnosis. Furthermore, current trea...

Read More

OmniNano Pharmaceuticals is a pharmaceutical technology startup located in Missouri City, TX. Omninano is developing nano-codelivery formulations with two drugs of distinct mechanisms of action for treating solid tumors. The foundational work has been done at the University of Texas MD Anderson Cancer Center and the University of Houston. Our lead product, ONP-001 is designed to treat pancreatic cancer. In 2022, 62,210 new pancreatic cases will be diagnosed in the US, with 49,830 deaths and a 5-year survival rate of only 11.5%. Extant drug therapies have very limited efficacy, with more than half of all pancreatic cancer patients dying within 12 months of diagnosis. Furthermore, current treatments can cause serious adverse effects that require costly mitigation. Pancreatic cancer is a difficult-to-treat disease with critical unmet needs. ONP-001, even administrated at a small fraction of conventional drug dosages, is shown to overcome drug resistance by depleting cancer stem cells and killing proliferating tumor cells. In animal studies, ONP-001 displays remarkable anti-tumor efficacy with minimal toxicity. To bring this novel drug to the clinic, OmniNano will conduct preclinical studies that will enable an Investigative New Drug (IND) application to the US Food and Drug Administration. Successful realization of the proposed project will enable clinical testing of ONP-001, an important milestone towards use in treating patients with pancreatic cancer.

Read Less